You are here

  • Home
  • Archive
  • Volume 10, Issue 11
  • Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

 

Online download statistics by month:

Online download statistics by month: November 2022 to September 2025

AbstractFullPdf
Nov 202229530169
Dec 2022324334120
Jan 202315215352
Feb 202314614730
Mar 2023959633
Apr 2023616125
May 2023454621
Jun 2023464714
Jul 2023383927
Aug 2023363821
Sep 2023333311
Oct 2023414116
Nov 2023616130
Dec 2023393924
Jan 2024363728
Feb 2024414123
Mar 2024515154
Apr 2024313128
May 2024474731
Jun 2024767639
Jul 2024686925
Aug 2024252414
Sep 2024545431
Oct 2024828251
Nov 202410610748
Dec 2024747631
Jan 2025838350
Feb 2025606050
Mar 2025444416
Apr 2025575718
May 2025585839
Jun 2025303025
Jul 2025110
Sep 2025110
Total243724651094